Oxxon's melanoma trial generates encouraging results
12th Sep 2005, 13:51 GMT
Interim data from a phase II immunotherapy study evaluating Oxxon Therapeutics' PrimeBoost technology in patients with advanced melanoma have shown the treatment to be safe and effective.
Latest news from Pharmaceutical Business Review Online:
- Celesio revenues, profits up
- Amgen arthritis drug shows sustained safety and efficacy
- Study supports cardiovascular safety of naproxen
- Cangene chickenpox drug granted orphan status
- Reata brain cancer therapy shows strong activity
- Novartis diabetes drug faces three month delay
- Favrille drug fails secondary goal
- Neurogen commences human testing of obesity drug
- Aeterna prostate cancer drug shows promise
- Isis says new drug effective against cholesterol